A Simple In Vitro Method to Determine Bactericidal Activity Against Mycobacterium abscessus Under Hypoxic Conditions
Open Access
- 13 March 2025
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 14 (3) , 299
Abstract
Background/Objectives: Non-replicating persisters (NRPs) of Mycobacterium abscessus are a bacterial subpopulation that can survive in the host under unfavorable conditions, such as hypoxia or nutrient starvation. The eradication of these bacteria is difficult, which is one reason for the long treatment duration and treatment failure. The drug discovery process should therefore contain methods to screen activity against NRPs. Methods: A hypoxic environment is used to generate NRPs of M. abscessus that are termed low-oxygen persisters (LOPs). For this, an oxidation process is used to transition a replicating culture of M. abscessus distributed in microtiter plates within a sealable box into LOPs. Colony counting, automated object counting, bactericidal activity determination of known agents, and confocal laser scanning microscopy are used to study the obtained culture. Results: The obtained culture shows typical attributes of non-replicating cells, such as significantly reduced replication, the reversibility of the LOP state under aerobic conditions, delayed regrowth on solid medium, altered morphological patterns on a single-cell level, and phenotypical resistance against a variety of clinically relevant antimycobacterial compounds. The study reveals metronidazole and niclosamide as bactericidal against M. abscessus LOPs. These compounds can be used as LOP verification compounds within the described model. Conclusions: Our model is easily implemented and quickly identifies compounds that are inactive under hypoxic conditions. It can therefore accelerate the identification of clinically effective antimycobacterial drug substances, and can be a helpful tool during the drug development process.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation (432291016, 2202)
- Mukoviszidose gGmbH (Bonn, Germany) (432291016, 2202)
This publication has 56 references indexed in Scilit:
- Determination of bactericidal activity against 3HC-2-Tre-labelled Mycobacterium abscessus (Mycobacteroides abscessus) by automated fluorescence microscopyJournal of Microbiological Methods, 2024
- Nα‐Aroyl‐N‐Aryl‐Phenylalanine Amides: A Promising Class of Antimycobacterial Agents Targeting the RNA PolymeraseChemistry & Biodiversity, 2024
- Structural characterization of a 3-hydroxychromone dye trehalose conjugate for fluorescent labelling of mycobacteriaJournal of Molecular Structure, 2023
- Treatment Approaches to Mycobacterium abscessus Pulmonary DiseaseClinics in Chest Medicine, 2023
- Treatment of Mycobacterium abscessus Pulmonary DiseaseChest, 2022
- Mycobacterium abscessusTrends in Microbiology, 2021
- Structural Basis of Mycobacterium tuberculosis Transcription and Transcription InhibitionMolecular Cell, 2017
- Towards a new tuberculosis drug: pyridomycin – nature's isoniazidEMBO Molecular Medicine, 2012
- A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilliJournal of Microbiological Methods, 2008
- Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancyTuberculosis, 2004